<![CDATA[<body bgcolor="#FFFFFF" text="#000000">
Incidence
Globally, Diabetes mellitus, better known as Type II Diabetes is one of the most burdensome chronic diseases which fast gaining epidemic proportions throughout the world.
The global prevalence of Type II Diabetes is estimated to double from 171 mn in 2000 to 334 mn by 2025.
Figure 1: Estimated number of people [in mn] globally with Diabetes
Spend on related treatment accounts for as much as 10 per cent of all healthcare dollars in the US.
In India, environmental and genetic factors, influenced by the changing socioeconomic scenario, have made an increasing number of Indians susceptible to this deadly epidemic. Projections place the number of diabetics to increase from 31.7 mn in 2000 to 79.4 mn in 2030.
In the table given below it can be seen that India leads the Top 10 with the highest number of people with diabetes in 2000 as well as 2030, with China and the USA occupying second and third positions respectively.
Ranking 2000 2030
Country People with Diabetes [mn] Country People with Diabetes [mn]
1 India 31.7 India 79.4
2 China 20.8 China 42.3
3 USA 17.7 USA 30.3
4 Indonesia 8.4 Indonesia 21.3
5 Japan 6.8 Pakistan 13.9
6 Pakistan 5.2 Brazil 11.3
7 Russian Federation 4.6 Bangladesh 11.1
8 Brazil 4.6 Japan 8.9
9 Italy 4.3 Philippines 7.8
10 Bangladesh 3.2 Egypt 6.7
Source: Wild S., Roglic G. et al – Global prevalence of Diabetes-Estimates for the year 2000
and projections for 2030.Diabetes Care; 27:1047-1053.
Treatment and DPP-IV
Globally, Diabetes mellitus, better known as Type II Diabetes is one of the most burdensome chronic diseases which fast gaining epidemic proportions throughout the world.
Type II Diabetes is associated with insulin resistance in peripheral tissues such as muscles and fat, impaired glucose-stimulated insulin secretion from pancreatic beta-cells and elevated hepatic gluconeogenesis.
Though certain drugs are available to treat the pathological conditions associated with Type II Diabetes, current pharmacotherapy does not adequately address the metabolic defects underlying this disease.
Glenmark Research Centre has been working on the Dipeptidylpeptidase IV [DPP-IV] target associated with glucose dependent insulin secretion and peripheral insulin resistance.
DPP-IV was selected because it contributes alternative pharmacological approaches to treat the distinct deficits that characterise the existing therapy of Type II Diabetes.
GRC 8200
Glenmark has discovered a lead compound GRC 8200. It is a potent, specific and orally bio-available inhibitor of the human DPP-IV enzyme.
The compound is currently undergoing preclinical studies being coordinated by Glenmark’s wholly owned Swiss subsidiary, GSA, and has shown a selectivity in animal models that is many times greater than the comparable DPP-IV inhibitors in Pipeline.
</body>]]>